2976-80-9

Basic information

• Product Name: 4-(Benzyloxy)cyclohexanol (cis / trans mixture)
• Synonyms: 4-(Benzyloxy)cyclohexanol (cis / trans mixture);4-(PhenylMethoxy)cyclohexanol;4-(benzyloxy)cyclohexanol;4-phenylmethoxycyclohexan-1-ol
• CAS NO: 2976-80-9
• Molecular Formula: C₁₃H₁₈O₂
• Molecular Weight: 206.283
• Product Categories: Aromatics;Miscellaneous Reagents;Aromatics, Miscellaneous Reagents
• Mol File: 2976-80-9.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 321.86°C at 760 mmHg
• Flash Point: 135.834°C
• Appearance: /
• Density: 1.078g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.543
• Storage Temp.: Refrigerator
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• CAS DataBase Reference: 4-(Benzyloxy)cyclohexanol (cis / trans mixture)(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(Benzyloxy)cyclohexanol (cis / trans mixture)(2976-80-9)
• EPA Substance Registry System: 4-(Benzyloxy)cyclohexanol (cis / trans mixture)(2976-80-9)

Safety Data

• Hazardous Substances Data: 2976-80-9(Hazardous Substances Data)

Usage

Chemical Properties

Light Yellow Oil

InChI:InChI=1/C13H18O2/c14-12-6-8-13(9-7-12)15-10-11-4-2-1-3-5-11/h1-5,12-14H,6-10H2

Upstream product

• 556-48-9 1,4-Cyclohexanediol 
• 100-39-0 benzyl bromide 
• 100-44-7 benzyl chloride 
• 87770-71-6 [4-(2-Methoxy-ethoxymethoxy)-cyclohexyloxymethyl]-benzene 
• 2987-06-6 4-(benzyloxy)cyclohexanone 
• 98-88-4 benzoyl chloride 
• 22428-87-1 4,4-ethylenedioxycyclohexan-1-ol 
• 92829-83-9 1,4-dioxaspiro<4,5>decan-8-ol benzyl ether 

Downstream Products

• 100864-60-6 methanesulfonic acid-(trans-4-benzyloxy-cyclohexyl ester) 
• 109557-52-0 trans-1-benzyloxy-4-(toluene-4-sulfonyloxy)-cyclohexane 
• 2987-06-6 4-(benzyloxy)cyclohexanone 
• 906318-29-4 4-ethyl-4-methoxy-cyclohexanol 
• 906318-24-9 4-methoxy-4-propyl-cyclohexanol 
• 906318-15-8 4-benzyloxy-1-methoxy-cyclohexanecarbonitrile 
• 906318-08-9 (4-allyl-4-methoxy-cyclohexyloxymethyl)-benzene 
• 906318-02-3 1-(4-benzyloxy-1-methoxy-cyclohexyl)-3-methyl-butan-2-one 
• 906318-01-2 [4-Methoxy-4-(3-methyl-2-methylene-butyl)-cyclohexyloxymethyl]-benzene 
• 220061-72-3 (4,4-dimethoxy-cyclohexyloxymethyl)-benzene 

Relevant articles and documents

P-Methylbenzyl Group: Oxidative Removal and Orthogonal Alcohol Deprotection

We describe the practical removal of p-methylbenzyl (MBn) protections of alcohols by treatment with 2,3-dichloro-5,6-dicyano-p-benzoquinone. When a molecule bears benzyl and MBn groups, the oxidant selectively removes the latter groups. Further, the MBn groups tolerate ceric ammonium nitrate, resulting in chemoselective removal of the p-methoxybenzyl group in the presence of the MBn groups. These orthogonal alcohol deprotections would provide novel synthetic strategies of organic compounds.

Hydrogen Borrowing Catalysis with Secondary Alcohols: A New Route for the Generation of β-Branched Carbonyl Compounds

A hydrogen borrowing reaction employing secondary alcohols and Ph? (Me5C6) ketones to give β-branched carbonyl products is described (21 examples). This new C-C bond forming process requires low loadings of [Cp?IrCl2]2, relatively low temperatures, and up to 2.0 equiv of the secondary alcohol. Substrate-induced diastereoselectivity was observed, and this represents the first example of a diastereoselective enolate hydrogen borrowing alkylation. By utilizing the Ph? group, the β-branched products could be straightforwardly cleaved to the corresponding esters or amides using a retro-Friedel-Crafts reaction. Finally, this protocol was applied to the synthesis of fragrance compound (±)-3-methyl-5-phenylpentanol.

CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS

This invention relates to a series of substituted cyclohexane containing analogues which are agonists of GPR119 intended to treat metabolic diseases mediated by GPR119 including Type I & II diabetes mellitus. Diabetes mellitus is an ever-increasing threat to human health causing various complications (blindness, kidney failure, neuropathy, heart attack, stroke, etc.). Recently it was found that activation of GPR119 which is highly expressed in pancreatic beta cells causes glucose dependent insulin secretion and GLP-1 release. Many pharmaceuticals are currently developing GPR119 agonists and herein we disclose alternative GPR119 agonists. Our invention describes GPR119 agonists having structural Formula (I), pharmaceutically acceptable salt or solvate of Formula (I), isomer or prodrug of Formula (I), and combination therapy of Formula (I) with other anti-diabetic drugs like DPP-IV inhibitors and/or insulin sensitizers.